Gastrointestinal Cancers (Issue 2) | Special Reports

Bevacizumab, Cetuximab Show Similar Benefit as First-Line Therapy in mCRC

August 14, 2014

Clinical Articles

A head-to-head comparison of cetuximab and bevacizumab showed equivalence for chemotherapy plus either agent in terms of OS, PFS, and response rates for patients with certain previously untreated mCRC.

An Analysis of Bevacizumab or Cetuximab for CRC

August 13, 2014

Clinical Articles

Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).

The Importance of Testing for BRAF Status in CRC Patients

August 13, 2014

Clinical Articles

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the importance of testing CRC patients for BRAF status.

Significant OS Benefit Seen With TAS-102 Monotherapy in Refractory mCRC

August 13, 2014

Clinical Articles

Significantly extended overall survival (OS) and progression-free survival (PFS) was seen with oral nucleoside TAS-102 treatment in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

Survival Benefit Confirmed With Palliative Resection in mCRC

August 13, 2014

Clinical Articles

Palliative care involving initial treatment with surgical resection of the primary tumor followed by systemic treatment yielded a 4.7-month OS benefit in patients with mCRC compared with the same treatments administered in the reverse order.